Last reviewed · How we verify
B: Peg-interferon alpha-2a & Ribavirin
Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.
Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | B: Peg-interferon alpha-2a & Ribavirin |
|---|---|
| Also known as | Pegasys & Robatrol |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Antiviral combination therapy |
| Target | Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Peg-interferon alpha-2a is a pegylated form of interferon alpha-2a that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including activation of natural killer cells and upregulation of MHC molecules. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, directly suppressing hepatitis C virus replication. The combination provides synergistic antiviral activity.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Anemia
- Neutropenia
- Depression/mood changes
- Headache
- Nausea
- Thrombocytopenia
Key clinical trials
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) (PHASE2)
- Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (PHASE2)
- Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) (PHASE4)
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (PHASE2)
- Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (PHASE4)
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype (PHASE2)
- A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: